Biocollection of Adult Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia, or High-risk Myelodysplastic Syndrome at Nantes University Hospital

What this Trial Is About

Researchers are collecting blood and bone marrow samples from patients with Acute Myeloid Leukemia AML, Acute Lymphocytic Leukemia ALL, or high-risk myelodysplastic syndrome MDS at Nantes University Hospital to support research. The goal is to analyze these samples to better understand these diseases and identify new biomarkers or therapeutic targets. This study is observational and aims to improve knowledge of tumor characteristics and their microenvironment in these conditions. Patients included in the study will provide additional blood or bone marrow samples only when these are already planned as part of their routine care. Samples may be collected at diagnosis or relapse and, depending on research needs, up to one additional sample each month for three months after inclusion. Collected samples will be sent to research laboratories immediately or stored for future analysis under the care of the clinical hematology department. Participants will be monitored through sample collections linked to their treatment schedule. Researchers will study genetic factors and plasma cytokine levels using advanced techniques like transcriptome analysis and flow cytometry. The main outcome is to characterize tumors and their environments to find new treatment targets, with results reviewed one year after inclusion. Participation involves no extra punctures beyond clinical care, and samples may be collected up to four times within three months after joining the biocollection.

Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored at the Nantes University Hospital